Prometic Life Scienc (PFSCF) 1.9600 $PFSCF
ProMetic Reports its 2015 Annual and Special Meeting of Shareholders Highlights
Marketwired - Wed May 13, 3:33PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported the highlights from its 2015 annual and special meeting of shareholders and Board of Directors election results.
PLI.TO: 2.38 (+0.06)
ProMetic Reports Its First Quarter 2015 Highlights and Financial Results
Marketwired - Wed May 13, 11:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported its first quarter 2015 results at its Annual General Meeting of its Shareholders. "Our first quarter 2015 financial results are broadly in line with our expectations. Our expenses are consistent with the number of clinical and pre-clinical assets being developed simultaneously by the company from both its small molecule and plasma-derived platforms", stated Mr. Bruce Pritchard, Chief Financial Officer of ProMetic Life Sciences Inc. "Although revenues were lower than in the first quarter of 2014, we anticipate that position to reverse as we progress through the year", added Mr. Pritchard.
PLI.TO: 2.38 (+0.06)
ProMetic to Develop C1 Esterase Inhibitor (C1-INH) as Its Next Plasma-Derived Drug Candidate
Marketwired - Thu May 07, 5:15AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema ("HAE" , a rare genetic disorder in which C1-INH is lacking. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the market to exceed US$3 billion by 2020.
PLI.TO: 2.38 (+0.06)
The Barbell Approach Builds Powerful Healthcare Stocks: StoneCastle's Bruce Campbell
Life Sciences Report - Seeking Alpha - Wed May 06, 8:49PM CDT
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments. He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this...
ProMetic Announces Closing of $50 M Bought Deal Offering of Common Shares
Marketwired - Wed May 06, 7:46AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by Canaccord Genuity Corp., and which included RBC Dominion Securities Inc., Beacon Securities Limited, TD Securities Inc. and Paradigm Capital Inc. (collectively, the "Underwriters" . ProMetic issued 19,250,000 common shares of the Corporation in connection with the Offering at a price of $2.60 per share for aggregate gross proceeds of $50,050,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission of 5% of the gross proceeds of the Offering.
PLI.TO: 2.38 (+0.06)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 109.30 (+0.56), PFE: 33.99 (+0.05), GALT: 2.76 (+0.07), FGEN: 20.38 (-1.01), CELGZ: 2.60 (-0.10)
ProMetic Life Science's (PFSCF) CEO Pierre Laurin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 5:29PM CDT
ProMetic Reports Its 2014 Fourth Quarter and Year End Highlights and Financial Results
Marketwired - Tue Mar 31, 8:22PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $23.0 million and a net profit of $2.6 million and revenues of $10.5 million and a net profit of $8.5 million for the year and quarter ended December 31, 2014 respectively. This compares to revenues of $20.6 million and a net loss of $17.4 million and revenues of $5.1 million and a net loss of $7.5 million for the year and quarter ended December 31, 2013 respectively.
PLI.TO: 2.38 (+0.06)
ProMetic to Report Its Fourth Quarter and Year End 2014 Financial Results and Hold Conference Call/Webcast
Marketwired - Mon Mar 30, 4:53PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014 on Tuesday March 31, 2015 after market hours.
PLI.TO: 2.38 (+0.06)
ProMetic Successfully Completes Its PBI-4050 Phase Ib in Patients With Chronic Kidney Disease ("CKD"
Marketwired - Thu Mar 19, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation" reported today that it has successfully completed its PBI-4050 Phase Ib multi-dose clinical trial in patients with chronic kidney disease. ProMetic's orally active lead drug candidate, PBI-4050, was found to be safe and well tolerated without any serious adverse events reported.
PLI.TO: 2.38 (+0.06)
ProMetic Announces Its Inclusion to the S&P/TSX Composite Index
Marketwired - Mon Mar 16, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it will be added to the S&P/TSX Composite Index ("Index" , effective after the close of trading on Friday, March 20, 2015, as a result of the quarterly review of the Index.
PLI.TO: 2.38 (+0.06)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 20.21 (-0.19), CBSTZ: 0.06 (unch), CNAT: 5.69 (-0.10), GALT: 2.76 (+0.07), NVO: 56.75 (+0.06), RPTP: 11.31 (-0.02), ISIS: 62.55 (+0.10), GILD: 109.30 (+0.56), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), TBRA: 14.00 (+0.55)
ProMetic Reports its 2015 Annual and Special Meeting of Shareholders Highlights
Marketwired - Wed May 13, 3:33PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported the highlights from its 2015 annual and special meeting of shareholders and Board of Directors election results. PLI.TO: 2.38 (+0.06)
ProMetic Reports Its First Quarter 2015 Highlights and Financial Results
Marketwired - Wed May 13, 11:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported its first quarter 2015 results at its Annual General Meeting of its Shareholders. "Our first quarter 2015 financial results are broadly in line with our expectations. Our expenses are consistent with the number of clinical and pre-clinical assets being developed simultaneously by the company from both its small molecule and plasma-derived platforms", stated Mr. Bruce Pritchard, Chief Financial Officer of ProMetic Life Sciences Inc. "Although revenues were lower than in the first quarter of 2014, we anticipate that position to reverse as we progress through the year", added Mr. Pritchard. PLI.TO: 2.38 (+0.06)
ProMetic to Develop C1 Esterase Inhibitor (C1-INH) as Its Next Plasma-Derived Drug Candidate
Marketwired - Thu May 07, 5:15AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema ("HAE" , a rare genetic disorder in which C1-INH is lacking. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the market to exceed US$3 billion by 2020. PLI.TO: 2.38 (+0.06)
The Barbell Approach Builds Powerful Healthcare Stocks: StoneCastle's Bruce Campbell
Life Sciences Report - Seeking Alpha - Wed May 06, 8:49PM CDT
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments. He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this...
ProMetic Announces Closing of $50 M Bought Deal Offering of Common Shares
Marketwired - Wed May 06, 7:46AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by Canaccord Genuity Corp., and which included RBC Dominion Securities Inc., Beacon Securities Limited, TD Securities Inc. and Paradigm Capital Inc. (collectively, the "Underwriters" . ProMetic issued 19,250,000 common shares of the Corporation in connection with the Offering at a price of $2.60 per share for aggregate gross proceeds of $50,050,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission of 5% of the gross proceeds of the Offering. PLI.TO: 2.38 (+0.06)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 109.30 (+0.56), PFE: 33.99 (+0.05), GALT: 2.76 (+0.07), FGEN: 20.38 (-1.01), CELGZ: 2.60 (-0.10)
ProMetic Life Science's (PFSCF) CEO Pierre Laurin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 5:29PM CDT
ProMetic Reports Its 2014 Fourth Quarter and Year End Highlights and Financial Results
Marketwired - Tue Mar 31, 8:22PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $23.0 million and a net profit of $2.6 million and revenues of $10.5 million and a net profit of $8.5 million for the year and quarter ended December 31, 2014 respectively. This compares to revenues of $20.6 million and a net loss of $17.4 million and revenues of $5.1 million and a net loss of $7.5 million for the year and quarter ended December 31, 2013 respectively. PLI.TO: 2.38 (+0.06)
ProMetic to Report Its Fourth Quarter and Year End 2014 Financial Results and Hold Conference Call/Webcast
Marketwired - Mon Mar 30, 4:53PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014 on Tuesday March 31, 2015 after market hours. PLI.TO: 2.38 (+0.06)
ProMetic Successfully Completes Its PBI-4050 Phase Ib in Patients With Chronic Kidney Disease ("CKD"
Marketwired - Thu Mar 19, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"
reported today that it has successfully completed its PBI-4050 Phase Ib multi-dose clinical trial in patients with chronic kidney disease. ProMetic's orally active lead drug candidate, PBI-4050, was found to be safe and well tolerated without any serious adverse events reported. PLI.TO: 2.38 (+0.06)
ProMetic Announces Its Inclusion to the S&P/TSX Composite Index
Marketwired - Mon Mar 16, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it will be added to the S&P/TSX Composite Index ("Index" , effective after the close of trading on Friday, March 20, 2015, as a result of the quarterly review of the Index. PLI.TO: 2.38 (+0.06)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 20.21 (-0.19), CBSTZ: 0.06 (unch), CNAT: 5.69 (-0.10), GALT: 2.76 (+0.07), NVO: 56.75 (+0.06), RPTP: 11.31 (-0.02), ISIS: 62.55 (+0.10), GILD: 109.30 (+0.56), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), TBRA: 14.00 (+0.55)
